New funding in the Delgoffe lab

Our lab is thrilled to to announce that we recently received two grants from the NIH:

  • Greg Delgoffe received the NIH Director’s New Innovator Award for his grant entitled "Exploring and exploiting metabolic plasticity in regulator T cells".
  • Graduate student Nicole Scharping received the National Cancer Institute Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) for her grant entitled "Tumor-infiltrating T cell metabolic dysfunction and genetic reprogramming for effective immunotherapy".

Congratulations all!

Finally, An Update!

Hello internet! Long time, no post! While this blog may have been relegated to the bottom of the to-do list, our science has not - our lab has been busy at both bench and keyboard to both better understand T cell metabolism in the tumor microenvironment. We have had some exciting milestones in the past couple of months, which we will briefly highlight in this post.

Presentations:

Our fearless leader, Dr. Greg Delgoffe, has had the opportunity to share our work at a number of national and international conferences in the past couple of months. He presented “Overcoming metabolic checkpoints to antitumor immunity” at the 9th Cellular Therapy Symposium in Erlangen, Germany, and at the 4th ImmunoTherapy Of Cancer Conference in Prague, Czech Republic. Greg also presented work on T cell metabolism at the American Transplant Congress in Chicago, Illinois and at the Transplantation Science Seminar in Victoria, British Columbia. Congrats, Greg!

New lab members:

While a few lab members have moved on to bigger and better things, we would like to formally welcome Dr. Dayana Rivadeneira (postdoctoral fellow) and McLane (Mac) Watson (graduate student)! Welcome to the lab guys!

New social media:

We are live on Twitter! Follow us @DelgoffeLab for day to day updates on lab news and events. We sign our tweets by hashtagging our initials, so you can see who has been tweeting.

That’s all for now, but not for long!

We have many exciting events coming along the pipeline - stay tuned to this blog or follow us on Twitter for updates!

Lab publishes work using metabolic remodeling to improve immunotherapy

Immunotherapy is likely hampered by a metabolically restrictive tumor microenvironment. This week in Cancer Immunology Research, our paper went live describing a role for the type II diabetes drug metformin as a metabolic remodeling agent that enables effective immunotherapy in mouse models!